The Experts below are selected from a list of 66 Experts worldwide ranked by ideXlab platform
Hifzur R Siddique - One of the best experts on this subject based on the ideXlab platform.
-
bmi1 drives metastasis of prostate cancer in caucasian and african american men and is a potential therapeutic Target Hypothesis tested in race specific models
Clinical Cancer Research, 2018Co-Authors: Arsheed A Ganaie, Firdous H Beigh, Matteo Astone, Marina G Ferrari, Raihana Maqbool, Syed Umbreen, Aijaz Parray, Hifzur R SiddiqueAbstract:Purpose: Metastasis is the major cause of mortality in prostate cancer patients. Factors such as genetic makeup and race play critical role in the outcome of therapies. This study was conducted to investigate the relevance of BMI1 in metastatic prostate cancer disease in Caucasian and African-Americans. Experimental Design: We employed race-specific prostate cancer models, clinical specimens, clinical data mining, gene-microarray, transcription-reporter assay, chromatin-immunoprecipitation (ChIP), IHC, transgenic-(tgfl/fl) zebrafish, and mouse metastasis models. Results: BMI1 expression was observed to be elevated in metastatic tumors (lymph nodes, lungs, bones, liver) of Caucasian and African-American prostate cancer patients. The comparative analysis of stage III/IV tumors showed an increased BMI1 expression in African-Americans than Caucasians. TCGA and NIH/GEO clinical data corroborated to our findings. We show that BMI1 expression (i) positively correlates to metastatic (MYC, VEGF, cyclin D1) and (ii) negative correlates to tumor suppressor (INKF4A/p16, PTEN) levels in tumors. The correlation was prominent in African-American tumors. We show that BMI1 regulates the transcriptional activation of MYC, VEGF, INKF4A/p16, and PTEN. We show the effect of pharmacological inhibition of BMI1 on the metastatic genome and invasiveness of tumor cells. Next, we show the anti-metastatic efficacy of BMI1-inhibitor in transgenic zebrafish and mouse metastasis models. Docetaxel as monotherapy has poor outcome on the growth of metastatic tumors. BMI1 inhibitor as an adjuvant improved the taxane therapy in race-based in vitro and in vivo models. Conclusions: BMI1, a major driver of metastasis, represents a promising therapeutic Target for treating advanced prostate cancer in patients (including those belonging to high-risk group).
Aijaz Parray - One of the best experts on this subject based on the ideXlab platform.
-
bmi1 drives metastasis of prostate cancer in caucasian and african american men and is a potential therapeutic Target Hypothesis tested in race specific models
Clinical Cancer Research, 2018Co-Authors: Arsheed A Ganaie, Firdous H Beigh, Matteo Astone, Marina G Ferrari, Raihana Maqbool, Syed Umbreen, Aijaz Parray, Hifzur R SiddiqueAbstract:Purpose: Metastasis is the major cause of mortality in prostate cancer patients. Factors such as genetic makeup and race play critical role in the outcome of therapies. This study was conducted to investigate the relevance of BMI1 in metastatic prostate cancer disease in Caucasian and African-Americans. Experimental Design: We employed race-specific prostate cancer models, clinical specimens, clinical data mining, gene-microarray, transcription-reporter assay, chromatin-immunoprecipitation (ChIP), IHC, transgenic-(tgfl/fl) zebrafish, and mouse metastasis models. Results: BMI1 expression was observed to be elevated in metastatic tumors (lymph nodes, lungs, bones, liver) of Caucasian and African-American prostate cancer patients. The comparative analysis of stage III/IV tumors showed an increased BMI1 expression in African-Americans than Caucasians. TCGA and NIH/GEO clinical data corroborated to our findings. We show that BMI1 expression (i) positively correlates to metastatic (MYC, VEGF, cyclin D1) and (ii) negative correlates to tumor suppressor (INKF4A/p16, PTEN) levels in tumors. The correlation was prominent in African-American tumors. We show that BMI1 regulates the transcriptional activation of MYC, VEGF, INKF4A/p16, and PTEN. We show the effect of pharmacological inhibition of BMI1 on the metastatic genome and invasiveness of tumor cells. Next, we show the anti-metastatic efficacy of BMI1-inhibitor in transgenic zebrafish and mouse metastasis models. Docetaxel as monotherapy has poor outcome on the growth of metastatic tumors. BMI1 inhibitor as an adjuvant improved the taxane therapy in race-based in vitro and in vivo models. Conclusions: BMI1, a major driver of metastasis, represents a promising therapeutic Target for treating advanced prostate cancer in patients (including those belonging to high-risk group).
Jim Sidanius - One of the best experts on this subject based on the ideXlab platform.
-
prejudice at the nexus of race and gender an outgroup male Target Hypothesis
Journal of Personality and Social Psychology, 2010Co-Authors: Carlos David Navarrete, Melissa M Mcdonald, Ludwin E Molina, Jim SidaniusAbstract:Adopting an evolutionary approach to the psychology of race bias, we posit that intergroup conflict perpetrated by male aggressors throughout human evolutionary history has shaped the psychology of modern forms of intergroup bias and that this psychology reflects the unique adaptive problems that differ between men and women in coping with male aggressors from groups other than one’s own. Here we report results across 4 studies consistent with this perspective, showing that race bias is moderated by gender differences in traits relevant to threat responses that differ in their adaptive utility between the sexes—namely, aggression and dominance motives for men and fear of sexual coercion for women. These results are consistent with the notion that the psychology of intergroup bias is generated by different psychological systems for men and women, and the results underscore the importance of considering the gender of the outgroup Target as well as the gender of the agent in psychological studies on prejudice and discrimination.
Valérie Simonneaux - One of the best experts on this subject based on the ideXlab platform.
-
effect of the camelid s seminal plasma ovulation inducing factor β ngf a kisspeptin Target Hypothesis
Frontiers in Veterinary Science, 2017Co-Authors: Khalid El Allali, Najlae El Bousmaki, Hassan Ainani, Valérie SimonneauxAbstract:Female mammals are classified into spontaneous and induced ovulators based on the mechanism eliciting ovulation. Ovulation in spontaneous species (e.g., human, sheep, cattle, horse, pigs, and most rodents) occurs at regular intervals and depends upon the circulating estradiol. However, in induced ovulators (e.g., rabbits, ferrets, cats, and camelids) ovulation is associated with coitus. In the later, various factors have been proposed to trigger ovulation, including auditory, visual, olfactory and mechanic stimuli. However, other studies have identified a biochemical component in the semen of induced ovulators responsible for the induction of ovulation and named accordingly ovulation inducing factor. In camelids, intramuscular or intrauterine administration of seminal plasma was shown to induce the preovulatory LH surge followed by ovulation and subsequent formation of corpus luteum. Recently, this ovulation inducing factor has been identified from seminal plasma as a neurotrophin, the nerve growth factor s (s-NGF). s-NGF is well known as promoting neuron survival and growth, but in this case, it appears to induce ovulation through an endocrine mode of action. Indeed, s-NGF may be absorbed through the endometrium to be conveyed, via the blood stream, to the central structures regulating the LH preovulatory surge. In this review we provide a summary of the most relevant results obtained in the field and we propose a working Hypothesis for the central action of s-NGF based on our recent demonstration of the presence of neurons expressing kisspeptin, a potent stimulator of GnRH/LH, in the camel hypothalamus.
-
Effect of the Camelid’s Seminal Plasma Ovulation-Inducing Factor/β-NGF: A Kisspeptin Target Hypothesis
Frontiers Media S.A., 2017Co-Authors: Khalid El Allali, Najlae El Bousmaki, Hassan Ainani, Valérie SimonneauxAbstract:Female mammals are classified into spontaneous and induced ovulators based on the mechanism eliciting ovulation. Ovulation in spontaneous species (e.g., human, sheep, cattle, horse, pigs, and most rodents) occurs at regular intervals and depends upon the circulating estradiol. However, in induced ovulators (e.g., rabbits, ferrets, cats, and camelids), ovulation is associated with coitus. In the later, various factors have been proposed to trigger ovulation, including auditory, visual, olfactory, and mechanic stimuli. However, other studies have identified a biochemical component in the semen of induced ovulators responsible for the induction of ovulation and named accordingly ovulation-inducing factor (OIF). In camelids, intramuscular or intrauterine administration of seminal plasma (SP) was shown to induce the preovulatory luteinizing hormone (LH) surge followed by ovulation and subsequent formation of corpus luteum. Recently, this OIF has been identified from SP as a neurotrophin, the β subunit of nerve growth factor (β-NGF). β-NGF is well known as promoting neuron survival and growth, but in this case, it appears to induce ovulation through an endocrine mode of action. Indeed, β-NGF may be absorbed through the endometrium to be conveyed, via the blood stream, to the central structures regulating the LH preovulatory surge. In this review, we provide a summary of the most relevant results obtained in the field, and we propose a working Hypothesis for the central action of β-NGF based on our recent demonstration of the presence of neurons expressing kisspeptin, a potent stimulator of GnRH/LH, in the camel hypothalamus
Arsheed A Ganaie - One of the best experts on this subject based on the ideXlab platform.
-
bmi1 drives metastasis of prostate cancer in caucasian and african american men and is a potential therapeutic Target Hypothesis tested in race specific models
Clinical Cancer Research, 2018Co-Authors: Arsheed A Ganaie, Firdous H Beigh, Matteo Astone, Marina G Ferrari, Raihana Maqbool, Syed Umbreen, Aijaz Parray, Hifzur R SiddiqueAbstract:Purpose: Metastasis is the major cause of mortality in prostate cancer patients. Factors such as genetic makeup and race play critical role in the outcome of therapies. This study was conducted to investigate the relevance of BMI1 in metastatic prostate cancer disease in Caucasian and African-Americans. Experimental Design: We employed race-specific prostate cancer models, clinical specimens, clinical data mining, gene-microarray, transcription-reporter assay, chromatin-immunoprecipitation (ChIP), IHC, transgenic-(tgfl/fl) zebrafish, and mouse metastasis models. Results: BMI1 expression was observed to be elevated in metastatic tumors (lymph nodes, lungs, bones, liver) of Caucasian and African-American prostate cancer patients. The comparative analysis of stage III/IV tumors showed an increased BMI1 expression in African-Americans than Caucasians. TCGA and NIH/GEO clinical data corroborated to our findings. We show that BMI1 expression (i) positively correlates to metastatic (MYC, VEGF, cyclin D1) and (ii) negative correlates to tumor suppressor (INKF4A/p16, PTEN) levels in tumors. The correlation was prominent in African-American tumors. We show that BMI1 regulates the transcriptional activation of MYC, VEGF, INKF4A/p16, and PTEN. We show the effect of pharmacological inhibition of BMI1 on the metastatic genome and invasiveness of tumor cells. Next, we show the anti-metastatic efficacy of BMI1-inhibitor in transgenic zebrafish and mouse metastasis models. Docetaxel as monotherapy has poor outcome on the growth of metastatic tumors. BMI1 inhibitor as an adjuvant improved the taxane therapy in race-based in vitro and in vivo models. Conclusions: BMI1, a major driver of metastasis, represents a promising therapeutic Target for treating advanced prostate cancer in patients (including those belonging to high-risk group).
